The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Regeneron
Consulting or Advisory Role - Regeneron
Speakers' Bureau - Regeneron
Research Funding - Amgen (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Regeneron
An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).
 
Mario Mandalà
Honoraria - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche/Genentech
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche/Genentech
Research Funding - Novartis (Inst); Roche/Genentech (Inst)
 
James M.G. Larkin
Honoraria - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer; Roche/Genentech
 
Paolo Antonio Ascierto
Consulting or Advisory Role - Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Genmab; Idera; Immunocore; Incyte; MedImmune; Merck Serono; Merck Sharp & Dohme; Newlink Genetics; Novartis; Pierre Fabre; Roche/Genentech; Sandoz; Sanofi; Sun Pharma; Syndax; Ultimovacs
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Michele Del Vecchio
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Pierre Fabre; Sanofi
 
Helen Gogas
Honoraria - Amgen; Bristol-Myers Squibb; MSD Oncology; Novartis; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche
Research Funding - Bristol-Myers Squibb; MSD Oncology; Novartis; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
C. Lance Cowey
No Relationships to Disclose
 
ANA Maria Arance Fernandez
Honoraria - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Roche
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; MSD; Roche
 
Stéphane Dalle
Employment - Sanofi Pasteur (I)
Stock and Other Ownership Interests - Sanofi Pasteur (I)
Consulting or Advisory Role - MSD (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Michael Schenker
Research Funding - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; BIOVEN; Bristol-Myers Squibb; Lilly; Merck Serono; Mylan; Novartis; Pfizer; Roche
 
Jean Jacques Grob
Honoraria - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
 
Vanna Chiarion-Sileni
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; MSD Oncology; Novartis; Pierre Fabre; Roche; Roche
Speakers' Bureau - Bristol-Myers Squibb; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Ivan Marquez-Rodas
Consulting or Advisory Role - Amgen; AstraZeneca; Bioncotech; Bristol-Myers Squibb; Incyte; Merck Serono; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Travel, Accommodations, Expenses - Bioncotech; Bristol-Myers Squibb; MSD; Roche
 
Marcus Butler
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Roche
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; EMD Serono; Genzyme; GlaxoSmithKline; Immunocore; Immunovaccine; Merck; Novartis
Research Funding - Merck; Takara Bio
Expert Testimony - Merck
 
Anna Maria Di Giacomo
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Pierre Fabre
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche/Genentech
 
Mark R. Middleton
Honoraria - Amgen; Roche
Consulting or Advisory Role - BiolineRx; Bristol-Myers Squibb; CytomX Therapeutics; Immunocore; Johnson & Johnson; Merck; Newlink Genetics; Novartis; RigonTEC
Research Funding - Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Replimune (Inst); RigonTEC (Inst); Roche (Inst); TC Biopharm (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Merck
 
Jose Lutzky
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Novartis
Speakers' Bureau - Array BioPharma; Novartis; Regeneron
Research Funding - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Elios Pharmaceutical; Genentech/Roche; Incyte; Merck; Merck Serono; Novartis; Pfizer; Viralytics
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer
 
Michael Millward
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pfizer/EMD Serono; Roche
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche
 
Veerle de Pril
Employment - Bristol-Myers Squibb
 
Maurice Lobo
Employment - Bristol-Myers Squibb
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Altor BioScience; Biond; CytomX Therapeutics
Honoraria - Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Merck; Moderna Therapeutics; Novartis; Oncorus; Roche; Sellas Life Sciences; Takeda; WindMIL
Consulting or Advisory Role - Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Jounce Therapeutics; Kirin Pharmaceuticals; Lion Biotechnologies; Merck; Moderna Therapeutics; Nektar; Novartis; Oncorus; Roche; Sellas Life Sciences; Takeda Science Foundation; WindMIL
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - named on a patent for 41BB induced TIL by Moffitt Cancer Center; named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Genentech; GlaxoSmithKline; Merck; Novartis; Roche; Takeda